Durham’s Chimerix pays $30M to secure rights for late-stage leukemia drug
This week, the Durham-based biopharmaceutical company announced an agreement with Cantex Pharmaceuticals for the worldwide license of CX-01.
Read More
leukemia
Paradigm shift in treatment of leukemia may be at hand
A paradigm shift is underway in the treatment of acute myeloid leukemia: The newest of personalized medicines proved more effective and less toxic than standard chemotherapy for certain acute myeloid leukemia patients, new research indicates
Read More
